

Guru-Index

Investing like the **the pros.**

Open End PERLES on the
Solactive Guru NTR Index

I. Guru – Investing like the pros

The Solactive Guru Net Total Return Index reflects the development of the top equity holdings of selected Hedge Funds and investment companies which principally invest in equities and follow a Buy-and-Hold strategy. While applying this strategy, good market knowledge and detailed analysis could make the difference between success and failure. For this reason, investment decisions of established hedge fund managers may be a valuable source of knowledge. The concept of the Solactive Guru Net Total Return Index is to tap into this knowledge.

II. Cost efficient access to hedge fund expertise

Hedge funds use significant resources for the search of attractive investment opportunities. That is why their investment decisions are often the result of a costly and time-consuming process. Hedge funds usually demand high fees from their investors to finance these expenses. It is not unusual that a volume based yearly management fee of 2% and a performance fee of 20% are charged.

The index provider Solactive uses a publicly accessible document for the determination of the components of the Solactive Guru Net Total Return Index, which every investment company in the U.S. that surpasses a certain amount of assets under management has to disclose. Since this document shows the top positions of every hedge fund, the Open End PERLES on the Solactive Guru Net Total Return Index allows investors to participate one to one in these top equity positions. A management fee of 1.20% p.a. applies

III. Why do U.S. investment companies and institutional investors have to disclose their positions?

The U.S. federal agency Securities and Exchange Commission (SEC) demands a minimum of transparency from every institutional investor with 100 million USD or more invested in U.S. equities. It includes a quarterly disclosure of every position held via the Form 13F. The name of this document comes from paragraph 13 (f) of the Securities Exchange Act, which demands the corresponding disclosure obligation since 1975. These companies are therefore obliged to disclose their equity positions within 45 days after the end of the quarter and to publish them on the SEC website.

For marketing purposes only



SSPA product type

Tracker certificates (1300)

Currency	Valor	SIX Symbol
CHF	25642236	GURUCH
USD	25642235	GURUUS

ubs.com/guru

Solactive Guru NTR Index vs. S&P 500 Index



	Solactive Guru NTR Index (USD)	S&P 500 Index
Return p.a.	20.0%	17.7%
Volatility p.a.	15.9%	13.7%
Sharpe Ratio	1.3	1.3

Source: Bloomberg, UBS / Period: 27.02.2009 to 09.05.2017

This chart represents a historical review before 27.02.2012 of the Solactive Guru Index. This historical data is not a reliable indicator for the future performance. Please note the back-testing disclaimer at the end of the document

IV. Diversified investment thanks to a smart index concept

The Solactive Guru Net Total Return Index was created by the index provider Solactive AG. The index calculation started at 100 index points on 25 May 2012. The Solactive Guru Net Total Return Index is calculated as a performance index. This means that possible dividends of the index members are reinvested in the index. The index is denominated in US-Dollars.

An adjustment of the index components takes place after the disclosure of the "13F" documents once in a quarter to capture changing hedge fund positions. In such a case, the index members are equally weighted. However, before the top holding of each investment management company is included in the Solactive Guru Net Total Return Index, the hedge fund is selected earlier in a multi stage process. This includes e.g. eliminating hedge funds with high turnover from the hedge fund pool. In such a way, the main focus of the index is on investment companies with a long term investment horizon and an investment style which can be described as "value-oriented". In this regard it should be pointed out that the "13F" filings used to select the stocks in the index are filed by each hedge fund approximately 45 days after the end of each calendar quarter. Therefore a given hedge fund may have already sold its position by the time of the "13F" filing and the rebalancing of the index.



V. Members of the Solactive Guru Net Total Return Index

Company	Weighting	Company	Weighting	Company	Weighting
Apple Inc	1.81%	Charter Communications Inc	1.83%	Cheniere Energy Inc	1.62%
Adient PLC	1.93%	Cigna Corp	1.82%	Southwest Airlines Co	1.66%
Autodesk Inc	1.83%	Cooper-Standard Holdings Inc	1.78%	LyondellBasell Industries NV	1.61%
Allergan PLC	1.66%	Delta Air Lines Inc	1.52%	Marriott International IncMD	1.82%
American Tower Corp	2.01%	Dycom Industries Inc	2.23%	Mondelez International Inc	1.69%
Amazon.com Inc	1.86%	Facebook Inc	1.89%	Macquarie Infrastructure Corp	1.77%
AutoNation Inc	1.57%	First Data Corp	1.64%	Microsoft Corp	1.80%
Aon PLC	1.76%	GrubHub Inc	1.97%	Netflix Inc	1.83%
Broadcom Ltd	1.85%	Home Depot Inc/The	1.88%	NXP Semiconductors NV	1.75%
Bank of America Corp	1.64%	Hess Corp	1.67%	Pioneer Natural Resources Co	1.49%
Sotheby's	1.94%	Herbalife Ltd	1.74%	Restaurant Brands Internationa	1.76%
Baidu Inc	1.74%	Humana Inc	1.82%	Reynolds American Inc	1.82%
Berkshire Hathaway Inc	1.70%	Horizon Pharma Plc	1.52%	Sprint Corp	1.69%
CBS Corp	1.74%	Incyte Corp	1.75%	Sherwin-Williams Co/The	1.84%
Crown Castle International Cor	1.81%	Investors Bancorp Inc	1.67%	Spirit AeroSystems Holdings In	1.70%
CDK Global Inc	1.71%	JPMorgan Chase & Co	1.65%	Extended Stay America Inc	1.72%
Celanese Corp	1.69%	Kraft Heinz Co/The	1.71%	Constellation Brands Inc	1.87%

As of: 09.05.2017

Source: Solactive (the current index composition and weighting is published daily on www.solactive.com)

VI. The product solution

The UBS Open End PERLES on the Solactive Guru Net Total Return Index track the performance of the underlying index, which reinvests any dividends from index members after deducting the management fee of 1.20 percent without limited maturity.

	CHF-Tranche	USD-Tranche
Issuer	UBS AG, London Branch	UBS AG, London Branch
SSPA product type	Tracker certificates (1300)	Tracker certificates (1300)
Conversion ratio	1:1	1:1
Management fee	1.20% p.a.	1.20% p.a.
Expiry	Open End	Open End
Underlying (Currency)	Solactive Guru Net Total Return Index (USD)	Solactive Guru Net Total Return Index (USD)
Issue price	CHF 165.73	USD 174.74
Listing date	05 November 2014	05 November 2014
ISIN / SIX Symbol	CH0256422368 / GURUCH	CH0256422350 / GURUUS

VII. Opportunities

- Investing like the pros, as the index components are chosen according to the published top holdings of carefully selected and well-established investment companies.
- Transparent and smart index concept, which uses the SEC disclosure obligation for investment companies with investments of 100 million USD or more in U.S. equities.
- Investments focus on U.S. equities.
- Diversification across the top holdings of selected Hedge Funds with quarterly rebalancing and equal weighting of the index members.
- Tradable every trading day under normal trading conditions.
- No fixed term restriction.

VIII. Risks

- No capital protection: investors run the risk of losing their investment if the price of the underlying index worsens.
- At the time of publication of the top holdings the actual portfolio of the investment companies might already have changed. It is thus possible that an adjustment in the Solactive Guru Net Total Return Index varies from the actual portfolio holdings of the selected investment companies.
- Investors bear the issuer risk and could lose their investment if the issuer files for bankruptcy.
- The issuer intends to ensure liquidity in normal market phases on trading days. However, investors should realize that they may not be able to buy /sell the product at any point in time.
- As the stocks included in the index may be listed in different currencies and the product does not have any currency hedges, the investor may also be exposed to an exchange rate risk, which may adversely affect the value of the product.
- The issuer has the right to terminate the product if certain conditions are met.

Investor profile

Solutions for investors with experience in stock market topics and structured products and with a medium to increased risk tolerance who would like to participate in the performance of the equities included in the index at little capital and administrative expense.

For other products and information on opportunities and risks visit: ubs.com/keyinvest

Disclaimer

These materials have been prepared by UBS AG and/or a subsidiary and/or an affiliate thereof ("UBS"). These materials are for distribution only under such circumstances as may be permitted by applicable law. They have not been prepared with regard to the specific investment objectives, financial situation or particular needs of any specific recipient. They are published solely for informational purposes and are not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments or to participate in any particular trading strategy. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. The recipient should not construe the contents of these materials as legal, tax, accounting, regulatory, or other specialist or technical advice or services or investment advice or a personal recommendation. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in these materials. No representation or warranty, either express or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein except with respect to information concerning UBS, nor is it intended to be a complete statement or summary of the securities markets or developments referred to in these materials or a guarantee that the services described herein comply with all applicable laws, rules and regulations. They should not be regarded by recipients as a substitute for the exercise of their own judgment. Any opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS as a result of using different assumptions and criteria. UBS is under no obligation to update or keep current the information contained herein, and past performance is not necessarily indicative of future results. UBS, its directors, officers, employees or clients may have or have had interest or long or short positions in the securities or other financial instruments referred to herein and may at any time make purchases and/or sales in them as principal or agent. UBS may act or have acted as market-maker in the securities or other financial instruments discussed in these materials. Furthermore, UBS may have or have had a relationship with or may provide or have provided investment banking, capital markets and/or other financial services to the relevant companies. Neither UBS nor any of its directors, officers, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of these materials or reliance upon the information contained herein. Additional information may be made available upon request. Clients wishing to effect transactions should contact their local sales representative.

This material contains data derived as a result of back-testing of data and is provided by UBS in good faith using its standard methodology for information of this kind. That methodology relies on proprietary models, empirical data, assumptions and such other information that we believe to be accurate and reasonable. The current data that UBS selected for preparation of this material may be substantially different if the date is selected from a different time period and this may have substantial impact on the back-testing results. This information is provided to you for information purpose only and we make no representation as to the accuracy, completeness or appropriateness of such methodology and accept no liability for your use of the information. Specifically, there is no assurance that other banks or brokers would derive the same results for the back-test period or that such results would have been achieved in practice. Potential investors should not rely on this material for the purpose of understanding the probability that they may lose their initial investment in investing in the subject product. Prospective investors should also note that back-testing results may project unrealistic expectation on the performance of the subject product. Past performance is not necessarily indicative of future results. This material does not guarantee the performance of the subject product in all circumstances and UBS shall not be responsible for any investment loss suffered by the investors in investing in the subject product in this respect. The back-testing results has not considered the risks involved in investing in the subject product, including but not limited to the credit risk of the issuer of the subject product. These risks may lead to the loss of investors' initial investment in the subject product and investors should read the risks stated in the offering documents of the subject product before investing in the subject product. Under no circumstances shall have any liability for a) any loss, damage or other injury in whole or in part caused by, resulting from or relating to, any error (negligent or otherwise) of UBS in connection with the compilation, methodology, interpretation, communication, publication or delivery of this analysis, or b) any direct, indirect, special, consequential, incidental or compensatory damages whatsoever (including, without limitation, lost profits), in either case caused by reliance upon or otherwise resulting from or relating to the use of (including the inability to use) this analysis. This analysis is confidential. You may not pass on this analysis to any third party without the express permission of UBS.

This information is communicated by UBS AG and/or its affiliates ("UBS"). * (see below) UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the product to which this [term sheet / document] relates (the "Structured Product"). UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this [term sheet / document]. UBS's trading and/or hedging activities related to the Structured Product may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier or relevant trigger event is crossed or triggered. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available. UBS may pay or receive brokerage or retrocession fees in connection with the Structured Product described herein. In respect of any Structured Product that is a security, UBS may, in certain circumstances, sell the Structured Product to dealers and other financial institutions at a discount to the issue price or rebate to them for their own account some proportion of the issue price. Further information is available on request. Structured Products are complex and may involve a high risk of loss. Prior to purchasing the Structured Product you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of the Structured Product) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in relation to the Product. UBS generally hedges its exposure to Structured Products, although it may elect not to hedge or to partially hedge any Structured Product. UBS's hedging activity may be conducted through transactions in the underlying asset, index or instrument or in options, futures or other derivatives related to the underlying asset, index or instrument on publicly traded markets or otherwise, and may have an impact on the price of the underlying asset. If a transaction is cash settled, UBS will generally unwind or offset any hedge it has for such Structured Product in close proximity to the relevant valuation time or period. In some cases, this activity may affect the value of the Structured Product. Unless stated otherwise in this document, (i) this document is for information purposes only and should not be construed as an offer, personal recommendation or solicitation to purchase the Structured Product and should not be treated as giving investment advice, and (ii) the terms of any investment in the Structured Product will be exclusively subject to the detailed provisions, including risk considerations, contained in the more detailed legal documentation that relates to the Structured Product (being the confirmation, information memorandum, prospectus or other issuer documentation as relevant). UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS's prior written permission. In respect of any Structured Product that is a security, no action has been or will be taken in any jurisdiction that would permit a public offering of the Product, save where explicitly stated in the issuer documentation. The Structured Product must be sold in accordance with all applicable selling restrictions in the jurisdictions in which it is sold.

UBS AG

P.O. Box, 8098 Zurich
E-mail: keyinvest@ubs.com

Hotline: +41-44-239 76 76*

Institutional Clients: +41-44-239 14 66*

Intermediaries: +41-44-239 77 60*

Wealth Management Clients: +41-44-239 68 00*

ubs.com/keyinvest

© UBS 2017. All rights reserved. UBS prohibits the forwarding of this information without the approval of UBS.

* Please note that calls to numbers marked with * may be recorded. When you call these numbers, we assume that you consent to this business practice.